November 22, 2024

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks

5 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Chronic Kidney Diseases, Clinical Development, commercial, lexicon, restructuring, setbacks, Surgical aspects, United States Food and Drug Administration

Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring

Empowering Women in Life Sciences: 2024’s Trailblazers in Biopharma R&D

5 months ago talkbio0Tagged 2024, Biological Science Disciplines, Biopharma, Fiercest, Gender, Health care facility, innovation, R&D, Women

Women in Life Sciences, Biopharma R&D, 2024’s Fiercest Women, Gender Balance, Innovation in Healthcare

Neurogene’s Rett Syndrome Trial Halted After Patient Death Linked to High-Dose Gene Therapy

5 months ago talkbio0Tagged AAVS1 gene, Clinical Trials, Complication, gene therapy, high-dose, Neurogene, Rett Syndrome

Neurogene, Rett syndrome, gene therapy, AAV, clinical trial, patient death, high-dose complications

AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction

5 months ago talkbio0Tagged Antifungal Agents, AstraZeneca, Clinical Trials, Drug Development, Opioid Use Disorder, Social Interaction

AstraZeneca, Opioid Use Disorder, Drug Development, Antifungal Interaction, Clinical Trials

Pyxis Oncology Faces Setback as Early ADC Readout in Solid Tumors Fails to Impress

5 months ago talkbio0Tagged Clinical Trials, Performance, PYX-201, Pyxis Oncology, Solid Neoplasm, therapeutic autologous dendritic cells

Pyxis Oncology, ADC, PYX-201, solid tumors, clinical trial, stock performance

Sonata Therapeutics Undergoes Restructuring: CEO Exits, 20 Staff Members Laid Off

5 months ago talkbio0Tagged CEO, departure - ActRelationshipType, Flagship, Pioneering, restructuring, Sonata, Staff

Sonata Therapeutics, Flagship Pioneering, CEO departure, staff layoffs, biotech restructuring

Halozyme Therapeutics Abandons $2.1 Billion Acquisition Bid for Evotec Due to Lack of Engagement

5 months ago talkbio0Tagged Acquisition, Evotec, Halozyme, Industry, Twice a day, Withdraw (activity)

Halozyme Therapeutics, Evotec, acquisition bid, withdrawal, lack of engagement, biotech industry

Enveda Secures $130 Million in Funding for Innovative Therapies in Inflammation, Obesity, and Beyond

5 months ago talkbio0Tagged Drug Development, Enveda, I&I, Inflammation, Microsoft-backed, Obesity, Pharma

Enveda, Microsoft-backed, $130M funding, Inflammation & Immunology (I&I), obesity, biotech, pharma, drug development

UCB’s Bimzelx Receives FDA Approval for Moderate-to-Severe Hidradenitis Suppurativa, Marking Fifth Indication

5 months ago talkbio0Tagged Approved, bimekizumab, Bimzelx, Chronic Inflammatory Skin Disease, Hidradenitis, IL-17F inhibitor, IL17A protein, human, suppurativa, United States Food and Drug Administration

Bimzelx, Bimekizumab, Hidradenitis Suppurativa, FDA Approval, IL-17A and IL-17F Inhibitor, Chronic Inflammatory Skin Disease

Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

5 months ago talkbio0Tagged Amylin, Calcitonin Receptor, GIP/, GLP-1, muscle mass, Next, Next-generation weight loss therapies, Obesity, Pep2Tango, Peptides, Tetra-receptor, Ventures, Versant

Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.